Long-term therapy with the guanine nucleoside analog penciclovir controls chronic duck hepatitis B virus infection in vivo

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 8, 1998, Pages 2132-2137

  Lin, Enjarn ^a   Luscombe, Carolyn ^a,c   Colledge, Danni ^a   Wang, Yan Yan ^a   Locarnini, Stephen ^a,b  

^a FAIRFIELD HOSPITAL   (Australia)

^b VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIMETHYL SULFOXIDE; NUCLEOSIDE ANALOG; PENCICLOVIR; PLACEBO; VIRUS DNA; VIRUS PROTEIN; VIRUS RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; DOT HYBRIDIZATION; DRUG EFFICACY; DRUG SAFETY; DUCK; HEPATITIS B VIRUS; IMMUNOHISTOCHEMISTRY; LONG TERM CARE; NONHUMAN; PRIORITY JOURNAL;

EID: 0031879931     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.8.2132     Document Type: Article

References (46)

1. Bishop, N., G. Civitico, Y. Wang, K. Guo, C. Birch, I. Gust, and S. Locarnini. 1990. Antiviral strategies in chronic hepatitis B virus infection. I. Establishment of an in vitro system using the duck hepatitis B virus model. J. Med. Virol. 31:82-89.
2. Boker, K. H. W., B. Ringe, M. Kruger, R. Pichlmayr, and M. P. Manns. 1994. Prostaglandin E plus famciclovir: a new concept for the treatment of severe hepatitis B after liver transplantation. Transplantation 57:1706-1708.
3. Boyd, M., S. Safrin, and E. Kern. 1993. Penciclovir: a review of its spectrum of activity, selectivity and cross-resistance pattern. Antiviral Chem. Chemother. 4(Suppl. 1):3-11.
4. Civitico, G., and S. Locarnini. 1994. The half-life of duck hepatitis B virus supercoiled DNA in congenitally infected primary hepatocyte cultures. Virology 203:81-89.
5. Dean, J., S. Bowden, and S. Locarnini. 1994. Reversion of duck hepatitis B virus DNA replication in vivo following cessation of treatment with the nucleoside analogue ganciclovir. Antivir. Res. 27:171-178.
6. Fourel, I., J. Saputelli, P. Schaffer, and W. Mason. 1994. The carbocyclic analogue of 2′-deoxyguanosine induces a prolonged inhibition of duck hepatitis B virus DNA synthesis in primary hepatocyte cultures and in the liver. J. Virol. 68:1059-1065.
7. Hoofnagle, J. H., and A. M. Di Bisceglie. 1997. The treatment of chronic viral hepatitis. N. Engl. J. Med. 336:347-356.
8. Ilsley, D., S.-H. Lee, W. Miller, and R. Kuchta. 1995. Acyclic guanosine analogs inhibit DNA polymerases α, δ, and ε with very different potencies and have unique mechanisms of action. Biochemistry 34:2504-2510.
9. Jilbert, A., J. Freiman, C. Burrell, M. Holmes, E. Gowans, R. Rowland, P. Hall, and Y. Cossart. 1988. Virus-liver cell interactions in duck hepatitis B virus infection: a study of virus dissemination within the liver. Gastroenterology 95:1375-1382.
10. Kane, M. A. 1996. Global status of hepatitis B immunization. Lancet 348:696.
11. Kejian, G., and D. S. Bowden. 1991. Digoxigenin-labeled probes for the detection of hepatitis B virus DNA in serum. J. Clin. Microbiol. 29:506-509.
12. Lee, B., W. Luo, S. Suzuki, M. Robins, and D. Tyrrell. 1989. In vitro and in vivo comparison of the abilities of purine and pyrimidine 2′,3′-dideoxynucleosides to inhibit duck hepadnavirus. Antimicrob. Agents Chemother. 33:336-339.
13. Lenhoff, R., and J. Summers. 1994. Coordinate regulation of replication and virus assembly by the large envelope protein of an avian hepadnavirus. J. Virol. 68:4565-4571.
14. Lenhoff, R., and J. Summers. 1994. Construction of avian hepadnavirus variants with enhanced replication and cytopathicity in primary hepatocytes. J. Virol. 68:5706-5713.
15. Lin, E., C. Luscombe, Y. Wang, T. Shaw, and S. Locarnini. 1996. The guanine nucleoside analog penciclovir is active against chronic duck hepatitis B virus infection in vivo. Antimicrob. Agents Chemother. 40:413-418.
16. Locarnini, S., and C. Luscombe. 1996. The pathogenic effects of antiviral therapy in chronic hepatitis B. Antivir. Ther. 1(Suppl. 4):59-63.
17. Lok, A. S. F. 1994. Treatment of chronic hepatitis B. J. Viral Hepatitis 1: 105-124.
18. Luscombe, C., J. Pedersen, S. Bowden, and S. Locarnini. 1994. Alterations in intrahepatic expression of duck hepatitis B viral markers with ganciclovir chemotherapy. Liver 14:182-192.
19. Luscombe, C., J. Pedersen, E. Uren, and S. Locarnini. 1996. Long-term ganciclovir chemotherapy of congenital duck hepatitis B virus infection in vivo: effect on intrahepatic viral DNA, RNA and protein expression. Hepatology 24:766-773.
20. Luscombe, C. A., and S. A. Locarnini. 1996. The mechanism of action of antiviral agents in chronic hepatitis B. Viral Hepatitis Rev. 2:1-35.
21. Main, J., J. Brown, C. Howells, R. Galassini, M. Crossey, P. Karayiannis, P. Georgiou, G. Atkinson and H. Thomas. 1996. A double-blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. J. Viral Hepatitis 3:211-215.
22. Mason, W., J. Cullen, J. Saputelli, T.-T. Wu, C. Liu, W. London, E. Lustbader, P. Schaffer, A. O'Connell, I. Fourel, C. Aldrich, and A. Jilbert. 1994. Characterisation of the antiviral effects of 2′ carbodeoxyguanosine in ducks congenitally infected with duck hepatitis B virus. Hepatology 19:398-411.
23. Milich, D. R., J. E. Jones, J. L. Hughes, J. Price, A. K. Raney, and A. McLachlan. 1990. Is a function of the secreted hepatitis Be antigen to induce immunological tolerance in utero? Proc. Natl. Acad. Sci. USA 87:6599-6603.
24. Newbold, J., H. Xin, M. Tencza, G. Sherman, J. Dean, S. Bowden, and S. Locarnini. 1995. The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes. J. Virol. 69:3350-3357.
25. Niu, J., Y. Wang, R. Dixon, S. Bowden, M. Qiao, L. Einck, and S. Locarnini. 1993. The use of ampligen alone and in combination with ganciclovir and coumermycin A1 for the treatment of ducks congenitally-infected with duck hepatitis B virus. Antivir. Res. 21:155-171.
26. Rashidi, M. R., J. A. Smith, S. E. Clarke, C. Beedham. 1997. In vitro oxidation of famciclovir and 6-deoxypenciclovir by aldehyde oxidase from human, guinea pig, rabbit, and rat liver. Drug Metab. Dispos. 25:805-813.
27. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
28. Seeger, C., and J. Maragos. 1991. Identification of a signal necessary for initiation of reverse transcription of the hepadnavirus genome. J. Virol. 65: 5190-5195.
29. Shaw, T., P. Amor, G. Civitico, M. Boyd, and S. Locarnini. 1994. In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus. Antimicrob. Agents Chemother. 38:719-723.
30. Shaw, T., and S. Locarnini. 1994. Hepatic purine and pyrimidine metabolism: implications for antiviral chemotherapy in viral hepatitis. Liver 15: 169-184.
31. Shaw, T., S.-S. Mok, and S. Locarnini. 1996. Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir. Hepatology 24:996-1002.
32. Speyer, J. 1985. Intraperitoneal chemotherapy: a possible role in the treatment of hepatic metastases, p. 225-235. In I. Bettino, R. Onfell, and W. Muggia (ed.), Liver cancer. Nijhoff. Boston, Mass.
33. Staschke, K., and J. Colacino. 1994. Priming of duck hepatitis B virus reverse transcription in vitro: premature termination of primer DNA induced by the 5′-triphosphate of fialuridine. J. Virol. 68:8265-8269.
34. Summers, J., and W. Mason. 1982. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell 29:403-415.
35. Summers, J., P. Smith, M. Huang, and M. Yu. 1991. Morphogenetic and regulatory mutations in the envelope proteins of an avian hepadnavirus. J. Virol. 65:1310-1317.
36. Trepo, C., P. Jesek, G. E. Atkinson, and R. J. Boon. 1996. Efficacy of famciclovir in chronic hepatitis B: results of a dose finding study. Hepatology 24:188A.
37. Tsiquaye, K., M. Slomka, and M. Muang. 1994. Oral famciclovir against hepatitis B virus replication in hepatic and nonhepatic tissues of ducklings infected in ovo. J. Med. Virol. 42:306-310.
38. Tsiquaye, K., D. Sutton, M. Muang, and M. Boyd. 1996. Antiviral activities and pharmacokinetics of penciclovir and famciclovir in Pekin ducks chronically infected with duck hepatitis B virus. Antivir. Chem. Chemother. 7:153-159.
39. Tuttleman, J., C. Pourcel, and J. Summers. 1986. Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell 47: 451-460.
40. Vere Hodge, R. 1993. Famciclovir and penciclovir. The mode of action of famciclovir including its conversion to penciclovir. Antivir. Chem. Chemother. 4:67-84.
41. Vere Hodge, R., and R. Perkins. 1989. Mode of action of 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine (BRL 39123) against herpes simplex virus in MRC-5 cells. Antimicrob. Agents Chemother. 33:223-229.
42. Wang, G., and C. Seeger. 1993. Novel mechanism for reverse transcription in hepatitis B viruses. J. Virol. 67:6507-6512.
43. Wang, Y., S. Bowden, T. Shaw, G. Civitico, M. Qiao, and S. Locarnini. 1991. Inhibition of duck hepatitis B virus replication in vivo by the nucleoside analogue ganciclovir (9-[2-hydroxy-1-(hydroxymethyl) ethoxymethyl] guanine). Antivir. Chem. Chemother. 2:107-114.
44. Wang, Y., C. Luscombe, S. Bowden, T. Shaw, and S. Locarnini. 1995. Inhibition of duck hepatitis B virus DNA replication by antiviral chemotherapy with ganciclovir-nalidixic acid. Antimicrob. Agents Chemother. 39:556-558.
45. Yokosuka, O., M. Omata, F. Imazeki, K. Okuda, and J. Summers. 1985. Changes of hepatitis B virus DNA in liver and serum caused by recombinant leukocyte interferon treatment: analysis of intrahepatic replicative hepatitis B virus DNA. Hepatology 5:728-734.
46. Zoulim, F., E. Dannaoui, and C. Trepo. 1995. Inhibitory effect of penciclovir on the priming of hepadnavirus reverse transcription, abstr. H13, p. 182. In Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.